Evidence map›Paper›PMID 33292733›Full record

ArticleCardio-oncology (London, England)2020

In ®Entresto we trust.

Massimiliano Camilli, Marco Giuseppe Del Buono, Pierantonio Menna, Giorgio Minotti

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Cardio-oncology (London, England), 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.7field-weighted citation impact, top 25% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 6 citations in OpenAlex.

  1. RSC advances · 2022
    Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 2 institutions in 1 country.

Massimiliano CamilliDepartment of Cardiovascular and Thoracic Sciences, Catholic University of the Sacred Heart, Rome, Italy.
Marco Giuseppe Del BuonoDepartment of Cardiovascular and Thoracic Sciences, Catholic University of the Sacred Heart, Rome, Italy.
Pierantonio MennaDepartment of Medicine, Center for Integrated Research and Unit of Drug Sciences, Campus Bio-Medico University, Via Alvaro Del Portillo 21, 00168, Rome, Italy.
Giorgio MinottiDepartment of Medicine, Center for Integrated Research and Unit of Drug Sciences, Campus Bio-Medico University, Via Alvaro Del Portillo 21, 00168, Rome, Italy. g.minotti@unicampus.it.
Università Campus Bio-Medico · ITUniversità Cattolica del Sacro Cuore · IT

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Sacubitril/Valsartan (S/V) is a novel and remarkably effective opportunity to treat heart failure with reduced ejection fraction (HFrEF). However, patients with HFrEF induced by cancer therapy were a priori excluded from the registration study. The value of S/V in this important subgroup of patients needs to be firmly established. In this issue of Cardio-Oncology, Gregorietti et al. report on the effects of S/V in a small group of cancer patients, primarily women with breast cancer treated with anthracyclines. The data are limited but seem to confirm the encouraging results of prior studies, paving the way to foster the use of S/V in cardio-oncology patients and hopefully, to design ad hoc prospective studies in this highly vulnerable population.

Indexed as

Cardio-oncologyHeart failureSacubitril/valsartan

Identifiers

PMID33292733
PMCPMC7643399
OpenAlexW3096480586

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.